Genmab A/S (NASDAQ:GMAB - Get Free Report) is scheduled to be announcing its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.28 per share for the quarter. Genmab A/S has set its FY 2024 guidance at EPS.Persons interested in listening to the company's earnings conference call can do so using this link.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The business had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Genmab A/S Price Performance
NASDAQ GMAB traded down $0.55 during trading hours on Wednesday, hitting $22.57. The company's stock had a trading volume of 882,343 shares, compared to its average volume of 650,474. The company's 50 day simple moving average is $25.16 and its two-hundred day simple moving average is $26.72. The company has a market cap of $14.94 billion, a P/E ratio of 18.75, a price-to-earnings-growth ratio of 0.68 and a beta of 0.98. Genmab A/S has a 12 month low of $22.39 and a 12 month high of $32.89.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the company. HC Wainwright restated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Wednesday, October 16th. Royal Bank of Canada upgraded Genmab A/S from a "sector perform" rating to an "outperform" rating in a research note on Monday, July 15th. Redburn Atlantic began coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They set a "buy" rating on the stock. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Genmab A/S in a report on Tuesday, August 20th. Finally, Morgan Stanley restated an "equal weight" rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Genmab A/S presently has an average rating of "Moderate Buy" and a consensus target price of $45.20.
Read Our Latest Research Report on Genmab A/S
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
